JPWO2018127819A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018127819A5 JPWO2018127819A5 JP2019556425A JP2019556425A JPWO2018127819A5 JP WO2018127819 A5 JPWO2018127819 A5 JP WO2018127819A5 JP 2019556425 A JP2019556425 A JP 2019556425A JP 2019556425 A JP2019556425 A JP 2019556425A JP WO2018127819 A5 JPWO2018127819 A5 JP WO2018127819A5
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- functionalized alginate
- hydrogen
- alkyl
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 106
- 229920000615 alginic acid Polymers 0.000 claims description 36
- 235000010443 alginic acid Nutrition 0.000 claims description 36
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 35
- 229940072056 alginate Drugs 0.000 claims description 35
- 230000000813 microbial effect Effects 0.000 claims description 32
- 239000002840 nitric oxide donor Substances 0.000 claims description 22
- 210000003097 mucus Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- -1 amino, hydroxyl Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000018537 nitric oxide storage Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000012026 peptide coupling reagents Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000010388 wound contraction Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 19
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000004005 nitrosamines Chemical class 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762441742P | 2017-01-03 | 2017-01-03 | |
| US62/441,742 | 2017-01-03 | ||
| US201762483505P | 2017-04-10 | 2017-04-10 | |
| US62/483,505 | 2017-04-10 | ||
| PCT/IB2018/050051 WO2018127819A1 (en) | 2017-01-03 | 2018-01-03 | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020504778A JP2020504778A (ja) | 2020-02-13 |
| JPWO2018127819A5 true JPWO2018127819A5 (https=) | 2022-11-18 |
| JP2020504778A5 JP2020504778A5 (https=) | 2022-11-18 |
| JP7366406B2 JP7366406B2 (ja) | 2023-10-23 |
Family
ID=62790817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556425A Active JP7366406B2 (ja) | 2017-01-03 | 2018-01-03 | 生分解性の抗菌性足場としての一酸化窒素放出性アルギン酸塩およびそれに関する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11072668B2 (https=) |
| EP (1) | EP3565848A4 (https=) |
| JP (1) | JP7366406B2 (https=) |
| CN (1) | CN110198959B (https=) |
| AU (2) | AU2018205823A1 (https=) |
| CA (1) | CA3048785A1 (https=) |
| WO (1) | WO2018127819A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018067838A1 (en) | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | S-nitrosothiol-mediated hyperbranched polyesters |
| WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| JP7403152B2 (ja) | 2017-03-28 | 2023-12-22 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景 |
| EP3710514B1 (en) | 2017-11-15 | 2023-06-07 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| KR102041246B1 (ko) * | 2018-12-21 | 2019-11-06 | 국립암센터 | 양쪽이온성 알긴산 유도체 및 이를 포함하는 조영제 조성물 |
| CN113383019B (zh) * | 2018-12-28 | 2023-11-17 | 北卡罗来纳大学教堂山分校 | 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法 |
| KR102203403B1 (ko) * | 2019-04-10 | 2021-01-15 | 주식회사 아이코어바이오 | 신규한 구조를 가지는 고분자, 이의 제조 방법, 고분자로부터 합성된 나노섬유 및 이의 제조 방법 |
| EP4093205A4 (en) * | 2020-02-07 | 2024-02-21 | KNOW Bio, LLC | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto |
| CN111410754B (zh) * | 2020-03-30 | 2021-06-25 | 暨南大学 | 一种s-亚硝基硫醇/多糖基原位成型水凝胶及其制备方法与应用 |
| GB202007928D0 (en) * | 2020-05-27 | 2020-07-08 | Attgeno Ab | New uses and methods |
| CN114652743B (zh) * | 2022-03-23 | 2024-10-15 | 南京师范大学 | 一种基于海藻酸钠的一氧化氮供体及其合成方法和应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169079A (en) | 1977-10-24 | 1979-09-25 | Iwao Tabushi | Polystyrene based polymers containing cyclodextrin derivatives, metal complexes of the same, and process for the production of the same |
| US5574027A (en) | 1989-11-22 | 1996-11-12 | Bernstein; Lawrence R. | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
| US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
| DE4210332C1 (https=) | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US6200558B1 (en) | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
| US5525357A (en) | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| AU685178B2 (en) | 1993-10-08 | 1998-01-15 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers |
| US5840759A (en) | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
| ATE192922T1 (de) | 1993-11-02 | 2000-06-15 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
| CH686873A5 (fr) | 1993-12-09 | 1996-07-31 | Lambert Jean Claude | Assortiment de jeux comportant chacun une planche de jeu et une série de pions. |
| CA2205564C (en) | 1994-11-22 | 2006-07-11 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pharmaceutical compositions comprising nitric oxide-releasing biopolymers |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US20030093143A1 (en) | 1999-03-01 | 2003-05-15 | Yiju Zhao | Medical device having surface depressions containing nitric oxide releasing compound |
| JP4285775B2 (ja) | 1996-09-27 | 2009-06-24 | アメリカ合衆国 | Ｏ▲上２▼―アリール化またはｏ▲上２▼―グリコシル化１―置換ジアゼン―１―イウム―１，２―ジオレート類およびｏ▲上２▼―置換１―［（２―カルボキシラト）ピロリジン―１―イル］ジアゼン―１―イウム―１，２―ジオレート類 |
| EP2292630B1 (en) | 1996-09-27 | 2015-11-25 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates |
| NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
| US6180082B1 (en) | 1997-11-24 | 2001-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method to enhance tissue accumulation of radiolabeled compounds |
| US6207855B1 (en) | 1998-06-23 | 2001-03-27 | Duke University Medical Center | Stable no-delivering compounds |
| US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
| JP4870314B2 (ja) | 2000-05-02 | 2012-02-08 | セラヴァンス， インコーポレーテッド | シクロデキストリンを含むグリコペプチド抗生物質組成物 |
| JP2002179647A (ja) | 2000-12-11 | 2002-06-26 | Kikkoman Corp | ニコチアナミン又はニコチアナミン含有物の製造法 |
| AUPR879601A0 (en) | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| DE60302454T2 (de) | 2002-04-19 | 2006-08-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen |
| US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| NO335366B1 (no) | 2002-07-26 | 2014-12-01 | Algipharma As | Mutantstamme Pf201 av Pseudomonas fluorescens og anvendelse derav i alginatproduksjon,samt fremgangsmåte for fremstilling derav. |
| NO20023581D0 (no) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat |
| BRPI0314042B8 (pt) | 2002-09-06 | 2021-05-25 | Calando Pharmaceuticals Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| US20050009789A1 (en) | 2003-05-13 | 2005-01-13 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service | Cyclooxygenase inhibition with nitroxyl |
| JP2005047979A (ja) | 2003-07-30 | 2005-02-24 | Dainippon Ink & Chem Inc | 多分岐ポリマーの製造方法、及び多分岐ポリマー |
| SG113562A1 (en) | 2004-01-12 | 2005-08-29 | Agency Science Tech & Res | Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents |
| CN101151037A (zh) | 2005-01-28 | 2008-03-26 | 平纳克尔医药股份有限公司 | 作为抗菌剂的β-环糊精衍生物 |
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| GB0515550D0 (en) | 2005-07-29 | 2005-09-07 | Univ Strathclyde | Inactivation of staphylococcus species |
| WO2007053292A2 (en) * | 2005-10-31 | 2007-05-10 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
| JP2009523584A (ja) | 2006-01-24 | 2009-06-25 | ミリメッド・アクティーゼルスカブ | Ｐｈ依存性薬物放出を有する医療デバイス |
| US7854923B2 (en) | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
| CN100441225C (zh) * | 2006-06-29 | 2008-12-10 | 上海交通大学 | 氨基酸改性壳聚糖亲核no供体及其合成方法 |
| GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
| CN101049513B (zh) | 2007-05-13 | 2010-05-19 | 刘万顺 | 水溶性壳聚糖基纤维止血愈创材料及其制备方法和应用 |
| ITMI20071341A1 (it) | 2007-07-05 | 2009-01-06 | Fidia Farmaceutici | Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no |
| EP2209472A1 (en) | 2007-10-12 | 2010-07-28 | The University of North Carolina at Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| HUE034051T2 (en) | 2007-11-27 | 2018-01-29 | Algipharma As | Use of alginate-containing oligomers to combat biofilms |
| US20090222088A1 (en) | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
| US20090232863A1 (en) | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
| EP2260060A4 (en) | 2008-04-01 | 2013-01-16 | Univ Cornell | ORGANIC SOLUBLE CHITOSA SALT AND CHITOSAN DERIVED BIOMATERIALS MANUFACTURED THEREFROM |
| CN102256989B (zh) | 2008-10-03 | 2016-01-06 | 聚糖生物科学有限责任公司 | 糖基化细菌代谢物的阴离子轭合物 |
| EP2398761A4 (en) | 2009-02-18 | 2015-11-04 | Bezwada Biomedical Llc | CONTROLLED RELEASE OF NITRIC OXIDE AND MEDICINES FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS |
| GB0904941D0 (en) | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
| US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
| US20120107229A1 (en) | 2009-04-15 | 2012-05-03 | Xuefei Huang | Novel nano-probes for molecular imaging and targeted therapy of diseases |
| US9539233B2 (en) | 2009-05-04 | 2017-01-10 | Aridis Pharmaceuticals Inc. | Gallium formulation for the treatment and prevention of infectious diseases |
| GB0909529D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
| ES2444541T3 (es) | 2009-06-03 | 2014-02-25 | Algipharma As | Oligómeros de alginato para usar para superar la multirresistencia a fármacos en bacterias |
| GB0909557D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Anti-microbial alginate oligomers |
| US9957341B2 (en) * | 2009-06-09 | 2018-05-01 | William Chambers | Biodegradable absorbent material and method of manufacture |
| CA2671595A1 (en) | 2009-07-09 | 2011-01-09 | Ping I. Lee | Controlled nitric oxide delivery from aqueous s-nitrosothiol conjugated polymers and their complexes |
| US8551456B2 (en) | 2010-03-05 | 2013-10-08 | University Of Dayton | Combination therapy and methods for treating bacterial biofilms |
| EP2547660B1 (en) | 2010-03-19 | 2015-01-07 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Nitroxyl (hno) releasing compounds and uses thereof in treating diseases |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| KR101255337B1 (ko) | 2010-10-04 | 2013-04-16 | 한국과학기술연구원 | 온도 감응성 합성 고분자를 이용한 일산화질소 전달체 |
| US9034355B2 (en) | 2011-02-24 | 2015-05-19 | Colorado State University Research Foundation | Materials for modulating biological responses and methods of making |
| WO2013029009A1 (en) | 2011-08-24 | 2013-02-28 | Novan, Inc. | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures |
| GB201116010D0 (en) | 2011-09-15 | 2011-10-26 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
| US9017653B2 (en) | 2012-06-14 | 2015-04-28 | The Board Of Regents Of The University Of Texas System | Nitric oxide-releasing compositions and methods |
| CN106986952B (zh) | 2012-08-17 | 2020-03-10 | 北卡罗来纳大学查珀尔希尔分校 | 水溶性的释放一氧化氮的聚葡糖胺和其用途 |
| WO2014138425A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Cyclosporine a-steroid conjugates |
| GB201322777D0 (en) | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
| JP2017501221A (ja) | 2013-12-23 | 2017-01-12 | ノルウェージャン ユニバーシティ オブ サイエンス アンド テクノロジー（エヌティーエヌユー） | がん治療におけるオリゴウロン酸塩の使用 |
| RU2016136449A (ru) | 2014-02-28 | 2018-04-02 | АльгиФарма АС | Применение олигометов альгината в лечении муковисцидоза и других состояний, ассоциированных с нарушенной функцией ионных каналов cftr |
| GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| WO2016073835A1 (en) | 2014-11-06 | 2016-05-12 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer |
| GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
| US11170451B2 (en) | 2015-10-02 | 2021-11-09 | Not So Forgetful, LLC | Apparatus and method for providing gift recommendations and social engagement reminders, storing personal information, and facilitating gift and social engagement recommendations for calendar-based social engagements through an interconnected social network |
| GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
| CN106046382B (zh) | 2016-05-25 | 2018-10-09 | 暨南大学 | 一种装载一氧化氮的阳离子聚合物及其制备方法和应用 |
| WO2018067838A1 (en) | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | S-nitrosothiol-mediated hyperbranched polyesters |
| WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| JP7403152B2 (ja) | 2017-03-28 | 2023-12-22 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景 |
| EP3710514B1 (en) | 2017-11-15 | 2023-06-07 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| US11102301B2 (en) | 2018-07-12 | 2021-08-24 | Sap Se | PCA-based scoring of the similarity of damage patterns of operational assets |
| CN113383019B (zh) | 2018-12-28 | 2023-11-17 | 北卡罗来纳大学教堂山分校 | 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法 |
-
2018
- 2018-01-03 WO PCT/IB2018/050051 patent/WO2018127819A1/en not_active Ceased
- 2018-01-03 JP JP2019556425A patent/JP7366406B2/ja active Active
- 2018-01-03 AU AU2018205823A patent/AU2018205823A1/en not_active Abandoned
- 2018-01-03 US US16/475,615 patent/US11072668B2/en active Active
- 2018-01-03 CA CA3048785A patent/CA3048785A1/en active Pending
- 2018-01-03 EP EP18736471.6A patent/EP3565848A4/en active Pending
- 2018-01-03 CN CN201880007216.7A patent/CN110198959B/zh active Active
-
2021
- 2021-07-26 US US17/385,497 patent/US11697693B2/en active Active
-
2022
- 2022-09-14 AU AU2022231716A patent/AU2022231716B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meng et al. | An overview of chitosan and its application in infectious diseases | |
| JPWO2018127819A5 (https=) | ||
| CN103732232B (zh) | 包含抗生素和分散剂或者抗粘结剂的组合物 | |
| US11786547B2 (en) | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | |
| CN108816689A (zh) | 一种具有长效抗菌性能的超亲水涂层及其制备方法 | |
| Ahonen et al. | Nitric oxide-releasing alginates | |
| CN101627092A (zh) | 使病毒和细菌失活的聚合涂料 | |
| CN102970995A (zh) | 稳定的抗菌组合物及方法 | |
| CN113801264B (zh) | 一种智能抗菌功能涂层的前驱聚合物及其制备方法与应用 | |
| CN112294752B (zh) | AgNPs@CSSCS纳米凝胶载药体系及其制备 | |
| JP2020504778A (ja) | 生分解性の抗菌性足場としての一酸化窒素放出性アルギン酸塩およびそれに関する方法 | |
| US20060002889A1 (en) | Polyionene polymers with hydrolyzable linkages | |
| CN107137762A (zh) | 一种医用钛或钛合金表面抗菌涂层的构建方法 | |
| Jin et al. | Recent advances in nanomedicine therapy for bacterial pneumonia | |
| Raheem et al. | ANTIBACTERIAL ACTIVITY OF SILVER NANOPARTICLES EXTRACTED FROM PROTEUS MIRABILIS AN D HEALING THE WOUND IN RABBIT. | |
| CN111281976A (zh) | 光热与化疗协同作用的功能化石墨烯靶向杀菌材料的制备方法与应用 | |
| JPWO2020139857A5 (https=) | ||
| CN105254913A (zh) | 一种表面兼有抗菌性和生物相容性的聚酯材料及制备与应用 | |
| JP2023527053A (ja) | 治療使用のためのモノ及びビスニトロシル化アルキルポリオール | |
| CN119158074A (zh) | 一种基于天然多糖的抗菌材料、制备方法及其应用 | |
| CN108030955A (zh) | 一种牙科种植体表面抗菌涂层的制备方法及其应用 | |
| US20240093006A1 (en) | Polycationic polysaccharide and application thereof | |
| CN120154635A (zh) | 应用消毒剂组合物进行病毒的传播预防 | |
| JP2006520329A (ja) | 抗菌作用を有し、ジアミンをベースとするグアニジン誘導体 | |
| Pandey et al. | Emerging concern with imminent therapeutic strategies for treating resistance in biofilm. Antibiotics 2022; 11: 476 |